NCT03871829: Phase 2: Retreatment in Participants With Myeloma Who Have Been Previously Rx with Dara

54767414MMY2065

NCT03871829: Phase 2: Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

DKd

Kd

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Sponsor

Janssen Research & Development, LLC

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT03871829

Official Title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab Retreatment

First Posted : March 12, 2019

Click here to see details on ClinicalTrials.gov

---

Drug: Carfilzomib 20 mg/m^2

Drug: Carfilzomib 70 mg/m^2

Drug: Dexamethasone 40 mg

Drug: Dara-SC 1800 mg

Drug: Dexamethasone 20 mg

---

Locations

United States, Arizona

United States, California

United States, Indiana

United States, Michigan

United States, Minnesota

United States, Missouri

United States, New York

United States, Ohio

United States, Texas

United States, Wisconsin

Canada, Alberta

Europe

France

Germany

Italy

Netherlands

Spain

Belgium

Denmark

Greece

Poland

Brazil

Asia

Russian Federation